In­cyte nabs sec­ond ap­proval with JAK in­hibitor cream for vi­tili­go

Fol­low­ing a three-month de­lay, the FDA has ap­proved In­cyte’s JAK in­hibitor Opzelu­ra for a sec­ond in­di­ca­tion: vi­tili­go.

With the new ap­proval, Opzelu­ra be­comes the first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER